Analyst Expectations For Viridian Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Viridian Therapeutics (NASDAQ:VRDN) has been analyzed by 12 analysts, showing a range of bullish to bearish perspectives. The average 12-month price target has increased by 8.26% to $38.25. Analysts have maintained or raised their ratings, with some setting high price targets up to $61.00. Despite positive analyst sentiment, Viridian faces financial challenges, including a revenue decline and negative profitability metrics.
October 28, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics has received mostly bullish analyst ratings, with an increased average price target of $38.25. Analysts have maintained or raised their ratings, indicating positive sentiment. However, the company faces financial challenges, including a revenue decline and negative profitability metrics.
The majority of analysts have given bullish ratings, and the average price target has increased, suggesting positive short-term sentiment. However, financial challenges such as revenue decline and negative profitability metrics may temper long-term optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100